Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

Mes dernières consult.
Most popular
Real-time Quote. Real-time Cboe BZX - 06/25 09:38:34 pm
185.605 USD   +0.25%
02:04pNASH play Akero emerges from stealth with $65M
12:42pAMGEN : Receives European Commission Approval to Add Overall Surviva..
09:43aLATEST BATCH OF : Rubius, Constellation, Replimune, Allakos
Analysis summary4-Traders Strategies
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Anaïs Lozach

share with twitter share with LinkedIn share with facebook
share via e-mail

Back on key levels based on weekly price data

Strategy published on 11/10/2017 | 14:31
long trade
Target price hit
Entry price : 173.15$ | Target : 192$ | Stop-loss : 164.9$ | Potential : 10.89%
Amgen shares are closing near attractive entry levels for a medium term horizon. Investors could regard the decline over the past weeks as a buying opportunity.
Investors have an opportunity to buy the stock and target the $ 192.
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

  • The close medium term support offers good timing for purchasing the stock.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 167.29 USD

  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
share with twitter share with LinkedIn share with facebook
share via e-mail
Recevoir les alertes

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 22 700 M
EBIT 2018 11 643 M
Net income 2018 8 740 M
Finance 2018 10 236 M
Yield 2018 2,80%
P/E ratio 2018 14,83
P/E ratio 2019 14,06
EV / Sales 2018 4,95x
EV / Sales 2019 4,90x
Capitalization 123 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Duration : Period : Week
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders